Can Biomarker-Guided biologics tame psoriasis and arthritis?

NCT ID NCT07149792

Recruiting now Disease control Sponsor: Taichung Veterans General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether using a person's unique biomarkers to choose their biologic treatment works better than the standard approach for psoriasis and psoriatic arthritis. About 50 adults in Taiwan will be randomly assigned to either a personalized selection group or a standard group. Researchers will track skin clearance, joint pain, and quality of life over up to 3 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: biologics
What this could lead to: If successful, this could show that choosing biologics based on individual biomarkers leads to better control of psoriasis and psoriatic arthritis symptoms.
What could go wrong: This is a small, early-phase trial with only 50 participants, so results may not apply to everyone. The approach may not prove better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIOLOGICS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIOLOGICS PSORIASIS PSORIASIS ARTHRITIS

Contacts and locations

Locations

Taichung Vertenans General Hospital
RECRUITING

Taichung, Taiwan, 886, Taiwan
Taichung Veterans Hospital
NOT_YET_RECRUITING

Taichung, Taiwan, 407219, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.